These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32468087)

  • 21. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock.
    Annane D; Renault A; Brun-Buisson C; Megarbane B; Quenot JP; Siami S; Cariou A; Forceville X; Schwebel C; Martin C; Timsit JF; Misset B; Ali Benali M; Colin G; Souweine B; Asehnoune K; Mercier E; Chimot L; Charpentier C; François B; Boulain T; Petitpas F; Constantin JM; Dhonneur G; Baudin F; Combes A; Bohé J; Loriferne JF; Amathieu R; Cook F; Slama M; Leroy O; Capellier G; Dargent A; Hissem T; Maxime V; Bellissant E;
    N Engl J Med; 2018 Mar; 378(9):809-818. PubMed ID: 29490185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock.
    Aikawa N; Takahashi T; Fujimi S; Yokoyama T; Yoshihara K; Ikeda T; Sadamitsu D; Momozawa M; Maruyama T
    J Infect Chemother; 2013 Oct; 19(5):931-40. PubMed ID: 23681364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy of vitamin C and thiamine for septic shock in a multicentre, double-blind, randomized, controlled study (ATESS): study protocol for a randomized controlled trial.
    Hwang SY; Park JE; Jo IJ; Kim S; Chung SP; Kong T; Shin J; Lee HJ; You KM; Jo YH; Kim D; Suh GJ; Kim T; Kim WY; Kim YJ; Ryoo SM; Choi SH; Shin TG;
    Trials; 2019 Jul; 20(1):420. PubMed ID: 31296251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling.
    Pinder N; Zimmermann JB; Gastine S; Würthwein G; Hempel G; Bruckner T; Hoppe-Tichy T; Weigand MA; Swoboda S
    Biomed Pharmacother; 2019 Oct; 118():109318. PubMed ID: 31398669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of physostigmine on recovery from septic shock following intra-abdominal infection - Results from a randomized, double-blind, placebo-controlled, monocentric pilot trial (Anticholium® per Se).
    Pinder N; Bruckner T; Lehmann M; Motsch J; Brenner T; Larmann J; Knebel P; Hoppe-Tichy T; Swoboda S; Weigand MA; Hofer S; Zimmermann JB
    J Crit Care; 2019 Aug; 52():126-135. PubMed ID: 31035187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of high doses of selenium, as sodium selenite, in septic shock patients a placebo-controlled, randomized, double-blind, multi-center phase II study--selenium and sepsis.
    Forceville X
    J Trace Elem Med Biol; 2007; 21 Suppl 1():62-5. PubMed ID: 18039501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study.
    de Kleijn ED; de Groot R; Hack CE; Mulder PG; Engl W; Moritz B; Joosten KF; Hazelzet JA
    Crit Care Med; 2003 Jun; 31(6):1839-47. PubMed ID: 12794428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
    Bakker J; Grover R; McLuckie A; Holzapfel L; Andersson J; Lodato R; Watson D; Grossman S; Donaldson J; Takala J;
    Crit Care Med; 2004 Jan; 32(1):1-12. PubMed ID: 14707554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
    McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
    Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
    Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
    Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First Clinical Experience with ONO-4232: A Randomized, Double-blind, Placebo-controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart Failure.
    Ward CL; Jamieson V; Nabata T; Sharpe J; Dozono K; Suto F; Hashimoto Y; Gussak I
    Clin Ther; 2016 May; 38(5):1109-21. PubMed ID: 27001444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial.
    Liu ZM; Chen J; Kou Q; Lin Q; Huang X; Tang Z; Kang Y; Li K; Zhou L; Song Q; Sun T; Zhao L; Wang X; He X; Wang C; Wu B; Lin J; Yuan S; Gu Q; Qian K; Shi X; Feng Y; Lin A; He X; ; Guan XD
    Intensive Care Med; 2018 Nov; 44(11):1816-1825. PubMed ID: 29971593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial.
    Annane D; Timsit JF; Megarbane B; Martin C; Misset B; Mourvillier B; Siami S; Chagnon JL; Constantin JM; Petitpas F; Souweine B; Amathieu R; Forceville X; Charpentier C; Tesnière A; Chastre J; Bohe J; Colin G; Cariou A; Renault A; Brun-Buisson C; Bellissant E;
    Am J Respir Crit Care Med; 2013 May; 187(10):1091-7. PubMed ID: 23525934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis.
    Mayorga AJ; Flores CM; Trudeau JJ; Moyer JA; Shalayda K; Dale M; Frustaci ME; Katz N; Manitpisitkul P; Treister R; Ratcliffe S; Romano G
    Scand J Pain; 2017 Oct; 17():134-143. PubMed ID: 28850367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ubiquinol (reduced Coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial.
    Donnino MW; Mortensen SJ; Andersen LW; Chase M; Berg KM; Balkema J; Radhakrishnan J; Gazmuri RJ; Liu X; Cocchi MN
    Crit Care; 2015 Jul; 19(1):275. PubMed ID: 26130237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial.
    Póvoa P; Salluh JI; Martinez ML; Guillamat-Prats R; Gallup D; Al-Khalidi HR; Thompson BT; Ranieri VM; Artigas A
    Crit Care; 2015 Apr; 19(1):193. PubMed ID: 25928214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
    Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
    Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
    Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
    Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
    Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.